These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2623329)

  • 61. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
    Boccardo F; Rubagotti A; Amoroso D; Mesiti M; Romeo D; Sismondi P; Giai M; Genta F; Pacini P; Distante V; Bolognesi A; Aldrighetti D; Farris A
    J Clin Oncol; 2000 Jul; 18(14):2718-27. PubMed ID: 10894871
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
    Bianco AR; De Placido S; Perrone F; Carlomagno C; De Laurentiis M; Del Mastro L; Lauria R; Marinelli A; Gallo C
    Ann N Y Acad Sci; 1993 Nov; 698():330-8. PubMed ID: 8279772
    [No Abstract]   [Full Text] [Related]  

  • 63. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
    Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
    JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 66. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
    Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
    J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Prospective randomized study of the efficacy of adjuvant hormone therapy in patients with breast cancer].
    Semiglazov VF; Moiseenko VM; Ivanova OA
    Vopr Onkol; 1986; 32(8):31-4. PubMed ID: 3532535
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
    Rivkin SE; Knight WA; McDivitt R; Cruz T; Foulkes M; Osborne CK; Fabian CJ; Costanzi JJ
    World J Surg; 1985 Oct; 9(5):723-7. PubMed ID: 3840629
    [No Abstract]   [Full Text] [Related]  

  • 69. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
    Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
    J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
    Partridge A; Gelber S; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Winer E
    Eur J Cancer; 2007 Jul; 43(11):1646-53. PubMed ID: 17512721
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Conservative surgery and irradiation (QUART) in the treatment of 243 stage I-II breast cancer patients.
    Gasparini G; Panizzoni GA; Dal Fior S; Germani B; Dall'Antonia F; Segato G; Meli S; Pozza F
    Anticancer Res; 1991; 11(4):1635-40. PubMed ID: 1746920
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 74. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
    Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
    Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
    Di Leo A; Buyse M
    J Clin Oncol; 2002 Apr; 20(7):1954-5. PubMed ID: 11919262
    [No Abstract]   [Full Text] [Related]  

  • 76. Testing "the soft option": trials of adjuvant endocrine therapy for the primary treatment of breast cancer.
    Ebbs SR; Baum M
    Isr J Med Sci; 1988; 24(9-10):552-6. PubMed ID: 3060445
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adjuvant chemotherapy combined with tamoxifen in postmenopausal patients with stage II breast cancer.
    Zielinski CC; Kubista E; Salzer H; Sevelda P; Langer M; Staffen A; Spona J; Aiginger P
    Lancet; 1986 Nov; 2(8516):1164. PubMed ID: 2877314
    [No Abstract]   [Full Text] [Related]  

  • 78. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B.
    Dombernowsky P; Brincker H; Hansen M; Mouridsen HT; Overgaard M; Panduro J; Rose C; Axelsson CK; Andersen J; Andersen KW
    Acta Oncol; 1988; 27(6A):691-7. PubMed ID: 3064774
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group.
    Eur J Cancer; 1992; 28A(4-5):904-7. PubMed ID: 1524921
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Adjuvant systemic therapy for breast cancer. Issues for primary care physicians.
    Berkowitz LD; Love N
    Postgrad Med; 1995 Oct; 98(4):85-8, 91, 94. PubMed ID: 7567725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.